Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

QVAR RediHaler Inhalation Aerosol Approved

Teva Pharmaceutical news release; 2017 Aug 7

Publish date:: August 22, 2017

The FDA has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol (Teva Pharmaceucials, Jerusalem), a maintenance treatment option designed to eliminate the need for hand-breath coordination during inhalation.

Indications: QVAR RediHaler is a corticosteroid indication for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.

Dosage and administration: Breath-actuated inhalation aerosol: 40 or 80 mcg per actuation.

Adverse reactions: The most common adverse reactions (incidence ≥3% and >placebo) include oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhinitis, oropharyngeal pain, and sinusitis.

Citation:

Teva announces FDA approval of QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol. [news release]. Jerusalem; Teva Pharmaceutical Industrial Ltd.; August 7, 2017: http://www.tevapharm.com/news/teva_announces_fda_approval_of_qvar_redihaler_beclomethasone_dipropionate_hfa_inhalation_aerosol_08_17.aspx. Accessed August 12, 2017.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis,

Treatment sequence with romosozumab influences osteoporosis outcomes,

Must Reads in Asthma

Statin Use Linked to Less Depression, Anxiety in ACOS Patients,

Don’t discount sleep disturbance for children with atopic dermatitis,

Antibiotic Therapy in Patients with Asthma, JAMA Intern Med; ePub 2019 Jan 28; Stefan, et al

Asthma Toolkit Improves Measures of Asthma Care, J Am Board Fam Med; 2019 Jan; Colborn, et al

Fractional Exhaled Nitric Oxide Testing in Asthma, Mayo Clin Proc; ePub 2017 Dec 20; Wang, et al